RPRX
Income statement / Annual
Last year (2023), Royalty Pharma plc's total revenue was $2.35 B,
an increase of 5.24% from the previous year.
In 2023, Royalty Pharma plc's net income was $1.13 B.
See Royalty Pharma plc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$2.35 B
|
$2.24 B
|
$2.29 B
|
$2.12 B
|
$1.81 B
|
$1.79 B
|
$1.60 B
|
$1.88 B
|
$1.65 B
|
| Cost of Revenue |
$560.66 M |
$5.67 M |
$23.00 M |
$88.11 M |
$1.02 B |
$135.96 M |
$33.27 M |
$0.00 |
$0.00 |
| Gross Profit |
$1.79 B |
$2.23 B |
$2.27 B |
$2.03 B |
$794.93 M |
$1.66 B |
$1.56 B |
$1.88 B |
$1.65 B |
| Gross Profit Ratio |
0.76 |
1 |
0.99 |
0.96 |
0.44 |
0.92 |
0.98 |
1 |
1 |
| Research and Development
Expenses |
$52.00 M
|
$177.11 M
|
$200.08 M
|
$26.00 M
|
$83.04 M
|
$392.61 M
|
$117.87 M
|
$91.02 M
|
$98.38 M
|
| General & Administrative
Expenses |
$249.75 M
|
$227.30 M
|
$182.83 M
|
$182.00 M
|
$103.44 M
|
$61.91 M
|
$106.44 M
|
$0.00
|
$0.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$249.75 M
|
$227.30 M
|
$182.83 M
|
$182.00 M
|
$103.44 M
|
$61.91 M
|
$106.44 M
|
$69.51 M
|
$121.42 M
|
| Other Expenses |
$560.66 M |
$909.91 M |
$475.84 M |
$319.00 M |
-$995.40 M |
-$1.52 M |
-$1.62 M |
-$925.80 M |
-$570.18 M |
| Operating Expenses |
$862.40 M |
$1.31 B |
$858.75 M |
$527.00 M |
-$808.92 M |
$430.45 M |
$658.24 M |
$1.09 B |
$789.98 M |
| Cost And Expenses |
$862.40 M |
$1.31 B |
$858.75 M |
$527.00 M |
-$808.92 M |
$430.45 M |
$658.24 M |
$1.15 B |
$858.14 M |
| Interest Income |
$72.29 M |
$78.34 M |
$53.54 M |
$28.38 M |
$22.33 M |
$24.44 M |
$6.76 M |
$0.00 |
$0.00 |
| Interest Expense |
$187.19 M |
$187.96 M |
$166.14 M |
$157.00 M |
$268.57 M |
$279.96 M |
$247.34 M |
$238.92 M |
$224.42 M |
| Depreciation &
Amortization |
$395.13 M
|
$5.67 M
|
$23.00 M
|
$23.06 M
|
$23.92 M
|
$33.27 M
|
$33.27 M
|
$68.20 M
|
$68.16 M
|
| EBITDA |
$1.89 B
|
$928.56 M
|
$1.45 B
|
$1.68 B
|
$2.65 B
|
$1.40 B
|
$972.96 M
|
$1.07 B
|
$862.44 M
|
| EBITDA Ratio |
0.8 |
0.44 |
0.65 |
0.89 |
1.45 |
0.79 |
0.71 |
0.42 |
0.52 |
| Operating Income Ratio
|
0.63
|
0.44
|
0.62
|
0.75
|
1.45
|
0.76
|
0.59
|
0.39
|
0.48
|
| Total Other
Income/Expenses Net |
$207.94 M
|
-$77.00 M
|
-$189.51 M
|
$106.56 M
|
-$161.76 M
|
$153.41 M
|
$403.49 M
|
$39.02 M
|
-$35.57 M
|
| Income Before Tax |
$1.70 B |
$230.06 M |
$1.24 B |
$1.70 B |
$2.46 B |
$1.52 B |
$1.34 B |
$761.90 M |
$758.71 M |
| Income Before Tax Ratio
|
0.72
|
0.1
|
0.54
|
0.8
|
1.36
|
0.85
|
0.84
|
0.41
|
0.46
|
| Income Tax Expense |
$0.00 |
$187.23 M |
$762.45 M |
$1.15 B |
$349.33 M |
$433.37 M |
$542.66 M |
$195.99 M |
$177.28 M |
| Net Income |
$1.13 B |
$42.83 M |
$478.75 M |
$495.20 M |
$2.35 B |
$1.38 B |
$1.21 B |
$565.91 M |
$581.43 M |
| Net Income Ratio |
0.48 |
0.02 |
0.21 |
0.23 |
1.29 |
0.77 |
0.76 |
0.3 |
0.35 |
| EPS |
3.41 |
0.0978 |
1.15 |
1.32 |
6.42 |
3.89 |
3.42 |
0.93 |
0.96 |
| EPS Diluted |
2.53 |
0.0978 |
1.15 |
1.32 |
6.42 |
3.89 |
3.42 |
0.93 |
0.96 |
| Weighted Average Shares
Out |
$447.60 M
|
$437.96 M
|
$414.79 M
|
$375.44 M
|
$365.90 M
|
$354.18 M
|
$354.18 M
|
$607.04 M
|
$607.04 M
|
| Weighted Average Shares
Out Diluted |
$602.90 M
|
$437.97 M
|
$414.80 M
|
$375.46 M
|
$365.90 M
|
$354.18 M
|
$354.18 M
|
$607.04 M
|
$607.04 M
|
| Link |
|
|
|
|
|
|
|
|
|
